Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CBM-C30.1 by AbelZeta for Non-Hodgkin Lymphoma: Likelihood of Approval
CBM-C30.1 is under clinical development by AbelZeta and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...
Data Insights
CBM-C30.1 by AbelZeta for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
CBM-C30.1 is under clinical development by AbelZeta and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...